⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

February 8, 2024Open Access

FIGURE 3 from Functional Heterogeneity in MET Pathway Activation in PDX Models of Osimertinib-resistant EGFR-driven Lung Cancer

Nitin Roper Rajaâ El Meskini Tapan K. Maity Devon Atkinson Amanda Day Nathan Pate Constance M. Cultraro Svetlana Pack Valerie Zgonc Zoë Weaver Ohler Udayan Guha

View Full Paper

Ask AI

Bookmark

Share

Abstract

Osimertinib and savolitinib combination suppresses AKT signaling in MET amplified osimertinib-resistant EGFR-mutant NSCLC PDXs. EGFR and MET pathway protein expression in MET amplified (A) and MET polysomy (B) LAT006 PDXs treated with either vehicle, osimertinib, savolitinib, and osimertinib plus savolitinib. Bar graphs show the relative quantification of phosphorylated proteins normalized to total protein expression in MET amplified (C) and MET polysomy (D) LAT006 PDXs.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Roper et al. (2024) studied this question.

synapsesocial.com/papers/68e7b940b6db64358770f89a https://doi.org/10.1158/2767-9764.25188612

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1FIGURE 2 from Functional Heterogeneity in MET Pathway Activation in PDX Models of Osimertinib-resistant EGFR-driven Lung Cancer2024
2FIGURE 4 from Functional Heterogeneity in MET Pathway Activation in PDX Models of Osimertinib-resistant EGFR-driven Lung Cancer2024
3Data from Functional Heterogeneity in MET Pathway Activation in PDX Models of Osimertinib-resistant EGFR-driven Lung Cancer2024
4FIGURE 1 from Functional Heterogeneity in MET Pathway Activation in PDX Models of Osimertinib-resistant EGFR-driven Lung Cancer2024
5FIGURE 5 from Functional Heterogeneity in MET Pathway Activation in PDX Models of Osimertinib-resistant EGFR-driven Lung Cancer2024